Patents by Inventor Marc Labelle

Marc Labelle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of histone demethylases
    Patent number: 10221139
    Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: March 5, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
  • Inhibitors of histone demethylases
    Patent number: 10189787
    Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: January 29, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
  • COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS
    Publication number: 20180099920
    Abstract: The present invention relates to compositions comprising compounds for use in treating, ameliorating and/or preventing neuromuscular disorders. The compounds as defined herein preferably inhibit the ClC-1 ion channel. The invention further relates to methods of treating, preventing and/or ameliorating neuromuscular disorders, by administering said composition to a person in need thereof.
    Type: Application
    Filed: June 15, 2016
    Publication date: April 12, 2018
    Applicant: NMD PHARMA APS
    Inventors: Thomas HOLM PEDERSEN, Martin BROCH-LIPS, Claus ELSBORG OLESEN, Marc LABELLE, Ole BÆKGAARD NIELSEN
  • INHIBITORS OF HISTONE DEMETHYLASES
    Publication number: 20170369444
    Abstract: Compounds of the form in which Q is selected from —COOH—CH?NR12, —W, —CH2NHR13, —CH=0 and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.
    Type: Application
    Filed: March 30, 2015
    Publication date: December 28, 2017
    Inventors: Marc Labelle, Rui Zhang, Cuthbert D. Martyr, Neerja Saraswat, Thomas Boesen
  • INHIBITORS OF HISTONE DEMETHYLASES
    Publication number: 20170320827
    Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Application
    Filed: February 17, 2017
    Publication date: November 9, 2017
    Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
  • Compounds and methods for inhibiting histone demethylases
    Patent number: 9802941
    Abstract: The present application relates to compounds being of Formula (I), (II), (III), (IV), (V), (VI), (IIIa), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), and (IIIg). Compounds of Formula (I) have the structure: wherein Q, R1, R18, R19, M, A and Y are as defined herein. The compounds of the application can modulate the activity of histone demethylases (HDMEs), and can be useful for the prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, e.g., cancer.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: October 31, 2017
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Thomas Boesen, Marc Labelle, Ying Yang, Neerja Saraswat, Dastagiri Dudekula, Cyril John Cook, Ramkrishna Reddy Vakiti, Rui Zhang, Farman Ullah
  • Inhibitors of histone demethylases
    Patent number: 9650339
    Abstract: Compounds of the form In which Q is selected from —CH?NR12, —W, —CH2NHR13, —CH?O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: May 16, 2017
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Marc Labelle, Thomas Boesen, Qasim Khan, Ramkrishna Reddy Vakiti, Utpal Sharma, Ying Yang, Mukund Mehrotra, Neerja Saraswat, Farman Ullah
  • Inhibitors of histone demethylases
    Patent number: 9611220
    Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: April 4, 2017
    Assignee: Gilead Sciences, Inc.
    Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
  • Inhibitors of histone demethylases
    Patent number: 9611219
    Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: April 4, 2017
    Assignee: Gilead Sciences, Inc.
    Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
  • INHIBITORS OF HISTONE DEMETHYLASES
    Publication number: 20160237037
    Abstract: Compounds of the form In which Q is selected from —CH?NR12, —W, —CH2NHR13, —CH?O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.
    Type: Application
    Filed: February 26, 2014
    Publication date: August 18, 2016
    Inventors: Marc Labelle, Thomas Boesen, Qasim Khan, Ramkrishna Reddy Vakiti, Utpal Sharma, Ying Yang, Mukund Mehrotra, Neerja Saraswat, Farman Ullah
  • COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES
    Publication number: 20160102096
    Abstract: The present application relates to compounds being of Formula (I), (II), (III), (IV), (V), (VI), (IIIa), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), and (IIIg). Compounds of Formula (I) have the structure: wherein Q, R1, R18, R19, M, A and Y are as defined herein. The compounds of the application can modulate the activity of histone demethylases (HDMEs), and can be useful for the prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, e.g., cancer.
    Type: Application
    Filed: August 26, 2015
    Publication date: April 14, 2016
    Inventors: Thomas Boesen, Marc Labelle, Ying Yang, Neerja Saraswat, Dastagiri Dudekula, Cyril John Cook, Ramkrishna Reddy Vakiti, Rui Zhang, Farman Ullah
  • Inhibitors of histone demethylases
    Patent number: 9221801
    Abstract: Compounds of the form In which Q is selected from —CH?NR12, —W, —CH2NHR13, —CH?O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: December 29, 2015
    Assignee: Epitherapeutics APS
    Inventors: Marc Labelle, Thomas Boesen, Qasim Khan, Ramkrishna Reddy Vakiti, Utpal Sharma, Ying Yang, Mukund Mehrotra, Neerja Saraswat, Farman Ullah
  • INHIBITORS OF HISTONE DEMETHYLASES
    Publication number: 20150203453
    Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Application
    Filed: October 1, 2013
    Publication date: July 23, 2015
    Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
  • INHIBITORS OF HISTONE DEMETHYLASES
    Publication number: 20140371214
    Abstract: Compounds of the form In which Q is selected from —CH?NR12, —W, —CH2NHR13, —CH?O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.
    Type: Application
    Filed: August 28, 2014
    Publication date: December 18, 2014
    Inventors: Marc Labelle, Thomas Boesen, Qasim Khan, Ramkrishna Reddy Vakiti, Utpal Sharma, Ying Yang, Mukund Mehrotra, Neerja Saraswat, Farman Ullah
  • INHIBITORS OF HISTONE DEMETHYLASES
    Publication number: 20140371195
    Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Application
    Filed: August 28, 2014
    Publication date: December 18, 2014
    Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
  • METHODS FOR TREATING ATHEROSCLEROSIS
    Publication number: 20130273024
    Abstract: The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, inflammation, thrombosis and other conditions and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.
    Type: Application
    Filed: March 26, 2013
    Publication date: October 17, 2013
    Inventors: Frank KAYSER, Marc Labelle, Bei Shan, Jian Zhang, Mingyue Zhou
  • Methods for treating atherosclerosis
    Patent number: 8426358
    Abstract: The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, inflammation, thrombosis and other conditions and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: April 23, 2013
    Assignee: Amgen Inc.
    Inventors: Frank Kayser, Marc Labelle, Bei Shan, Jian Zhang, Mingyue Zhou
  • METHODS FOR TREATING ATHEROSCLEROSIS
    Publication number: 20110206652
    Abstract: The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, inflammation, thrombosis and other conditions and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.
    Type: Application
    Filed: April 14, 2011
    Publication date: August 25, 2011
    Applicant: Amgen Inc.
    Inventors: Frank Kayser, Marc Labelle, Bei Shan, Jian Zhang, Mingyue Zhou
  • Arylsulfones and uses related thereto
    Patent number: 7754890
    Abstract: Aryl sulfone compounds of formula I and II are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: July 13, 2010
    Assignee: Amgen Inc.
    Inventors: Pingchen Fan, Hiroyuki Goto, Xiao He, Makoto Kakutani, Marc Labelle, Dustin L. McMinn, Jay P. Powers, Yosup Rew, Daqing Sun, Xuelei Yan
  • Antiinflammation agents
    Patent number: 7635695
    Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: December 22, 2009
    Assignee: Amgen Inc.
    Inventors: Simon A. Burkitt, Mario G. Cardozo, Timothy D. Cushing, Michael R. DeGraffenreid, Christopher N. Farthing, Xiaolin Hao, Juan C. Jaen, Xian Yun Jiao, David J. Kopecky, Marc Labelle, Sarah E. Lively, Dustin L. McMinn, Sven P. Rasmussen, Youngsook Shin, Marie-Louise Smith, Andrew Smith